Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Estrogen Receptor-positive|HER2/Neu Negative
Interventions: DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: Idasanutlin
Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: Genentech, Inc.|Stand Up To Cancer